Trial Profile
Korean Post-marketing Surveillance for Onglyza
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 22 Sep 2016 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2014 Planned End Date changed from 1 Jan 2017 to 1 May 2017 reported by ClinicalTrials.gov.